Related Experiment Video
Updated: Sep 28, 2025
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
Compound Danshen dripping pills in treating with coronary heart disease: A protocol for systematic review and
1Department of Pharmacy, Lianyungang Oriental Hospital, Lianyungang, Jiangsu, China.
Insights
This study will systematically review randomized controlled trials to assess the effectiveness and safety of compound Danshen dripping pills (CDDPs) for treating coronary heart disease (CHD). The meta-analysis aims to provide evidence-based clinical practice guidelines for CDDP use in CHD patients.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Evidence-Based Medicine
Background:
- Coronary heart disease (CHD) is a leading cause of mortality, characterized by vascular stenosis leading to myocardial ischemia and necrosis.
- CHD significantly impacts the quality of life for middle-aged and older populations.
- Compound Danshen dripping pills (CDDPs) are a common Chinese patent medicine for CHD, but evidence on their efficacy and safety is limited.
Purpose of the Study:
- To conduct a systematic review and meta-analysis evaluating the efficacy and safety of CDDPs in treating CHD patients.
- To provide evidence-based clinical practice recommendations for CDDP use in cardiovascular care.
- To address the lack of robust clinical evidence supporting the use of CDDPs for CHD.
Main Methods:
- A systematic search of randomized controlled trials (RCTs) will be conducted across major databases (MEDLINE, Cochrane, EMBASE, CNKI, WanFang) up to January 3, 2022.
- Data extraction will include study design, participant characteristics, intervention details, and outcomes. The Cochrane risk of bias tool will assess trial quality.
- Meta-analysis will employ random-effects or fixed-effects models, presenting results as risk ratios and weighted mean differences. Publication bias will be assessed using funnel plots.
Main Results:
- This section is to be populated upon completion of the meta-analysis.
- The study anticipates quantifying the effect of CDDPs on CHD outcomes.
- Safety data regarding CDDPs in CHD patients will be analyzed.
Conclusions:
- This meta-analysis will provide a comprehensive evaluation of CDDPs for CHD treatment.
- Findings will inform clinical decision-making regarding the use of CDDPs in cardiovascular medicine.
- The study aims to contribute to the evidence base for traditional Chinese medicine in managing CHD.
Background:
Coronary heart disease (CHD) patients are categorized by occlusion or vascular stenosis leading to myocardial ischemia, hypoxia, and necrosis. In clinical cardiovascular, CHD remains as a leading disease that is primarily prevalent among older people and mid-aged groups. CHD has a drastic impact on their life standard, and is known to have debilitating effects on both mental and physical wellbeing. As a Chinese patent medicine, compound Danshen dripping pills (CDDPs) are commonly administered to treat CHD in China. Despite the common intake of CDDPs, there is a lack of evidence-based clinical practice to inform its efficacy and safety through related systematic reviews. Therefore, the present protocol proposes to conduct a meta-analysis aiming to evaluate the effectivity and safeness of using CDDP for treating CHD patients.
Methods:
Randomized controlled trials that have evaluated the efficacy and safety of CDDP for treating CHD patients will be searched in MEDLINE, Cochrane Library, EMBASE, China National Knowledge Infrastructure, and WanFang databases. The search will include all related articles published till January 3, 2022. The extracted data will include information on study design, characteristics of the participants, details on intervention, and outcomes. Cochrane risk of bias tool will be employed to assess the quality of the trials. We will use either a random-effects model or fixed-effects model to pool the data. We will present the results as a risk ratio for dichotomous data and weighted mean difference for continuous data. We will visualize publication bias using funnel plots. Disagreements shall be resolved through discussion.
Ethics And Dissemination:
Not required.
Osf Registration Number:
10.17605/OSF.IO/HJTP8.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:26Coronary Artery Disease IV: Preventive Measures
01:27Peripheral Artery Disease III: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Angina IV: Management
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System